BALOXAVIR MARBOXIL - Generic Drug Details

What are the generic sources for baloxavir marboxil and what is the scope of freedom to operate?

Baloxavir marboxil is the generic ingredient in two branded drugs marketed by Genentech Inc and Norwich, and is included in three NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Baloxavir marboxil has two hundred and sixty-six patent family members in forty-two countries.

Two suppliers are listed for this compound.

Summary for BALOXAVIR MARBOXIL

International Patents:	266
US Patents:	10
Tradenames:	2
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	60
Clinical Trials:	17
Patent Applications:	823
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BALOXAVIR MARBOXIL
What excipients (inactive ingredients) are in BALOXAVIR MARBOXIL?	BALOXAVIR MARBOXIL excipients list
DailyMed Link:	BALOXAVIR MARBOXIL at DailyMed

Recent Clinical Trials for BALOXAVIR MARBOXIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chinese Academy of Medical Sciences	NA
China-Japan Friendship Hospital	NA
Ente Ospedaliero Cantonale, Ticino, Switzerland	PHASE3

See all BALOXAVIR MARBOXIL clinical trials

Pharmacology for BALOXAVIR MARBOXIL

Drug Class	Polymerase Acidic Endonuclease Inhibitor
Mechanism of Action	Chelating Activity Polymerase Acidic Endonuclease Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for BALOXAVIR MARBOXIL

J05AX	Other antivirals
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for BALOXAVIR MARBOXIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XOFLUZA	Tablets	baloxavir marboxil	40 mg and 80 mg	210854	1	2022-10-24

US Patents and Regulatory Information for BALOXAVIR MARBOXIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genentech Inc	XOFLUZA	baloxavir marboxil	FOR SUSPENSION;ORAL	214410-001	Nov 23, 2020		RX	Yes	Yes
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-003	Mar 18, 2021	AB	RX	Yes	Yes	10,633,397
Genentech Inc	XOFLUZA	baloxavir marboxil	FOR SUSPENSION;ORAL	214410-002	May 30, 2025		RX	Yes	No	11,306,106
Genentech Inc	XOFLUZA	baloxavir marboxil	TABLET;ORAL	210854-001	Oct 24, 2018		DISCN	Yes	No	8,927,710		Y
Genentech Inc	XOFLUZA	baloxavir marboxil	FOR SUSPENSION;ORAL	214410-003	May 30, 2025		RX	Yes	Yes
Genentech Inc	XOFLUZA	baloxavir marboxil	FOR SUSPENSION;ORAL	214410-001	Nov 23, 2020		RX	Yes	Yes	8,927,710		Y
Genentech Inc	XOFLUZA	baloxavir marboxil	FOR SUSPENSION;ORAL	214410-001	Nov 23, 2020		RX	Yes	Yes	10,759,814		Y	Y

EU/EMA Drug Approvals for BALOXAVIR MARBOXIL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Roche Registration GmbH	Xofluza	baloxavir marboxil	EMEA/H/C/004974Treatment of influenzaXofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above.Post exposure prophylaxis of influenzaXofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above.Xofluza should be used in accordance with official recommendations.	Authorised	no	no	no	2021-01-07

International Patents for BALOXAVIR MARBOXIL

Country	Patent Number	Title	Estimated Expiration
Argentina	104428
Australia	2016256125
Brazil	112017022550
Canada	2984130
Chile	2017002711
China	107709321
China	112876473

Supplementary Protection Certificates for BALOXAVIR MARBOXIL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2620436	21C1012	France		PRODUCT NAME: BALOXAVIR MARBOXIL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/20/1500 20210108
2620436	SPC/GB21/036	United Kingdom		PRODUCT NAME: BALOXAVIR MARBOXIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF.; REGISTERED: UK EU/1/20/1500(FOR NI) 20210108; UK MORE ON HISTORY TAB 20210108
2620436	C202130015	Spain		PRODUCT NAME: BALOXAVIR MARBOXIL; NATIONAL AUTHORISATION NUMBER: EU/1/20/1500; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1500; DATE OF FIRST AUTHORISATION IN EEA: 20210107
2620436	CA 2021 00004	Denmark		PRODUCT NAME: BALOXAVIR MARBOXIL ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/20/1500 20210108
3428170	LUC00198	Luxembourg		PRODUCT NAME: BALOXAVIR MARBOXIL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1500 20210108
2620436	202140003	Slovenia		PRODUCT NAME: BALOXAVIR MARBOXIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/20/1500; DATE OF NATIONAL AUTHORISATION: 20210107; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2620436	7/2021	Austria		PRODUCT NAME: BALOXAVIR MARBOXIL ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/20/1500 (MITTEILUNG) 20210108

Baloxavir Marboxil: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Baloxavir marboxil, marketed as Xofluza, is a first-in-class antiviral medication targeting influenza. Its unique mechanism of action, inhibiting the cap-dependent endonuclease activity of the influenza virus polymerase acidic protein, differentiates it from traditional neuraminidase inhibitors. This report analyzes the market landscape, patent status, and projected financial trajectory of baloxavir marboxil.

What is the Current Market Position of Baloxavir Marboxil?

Baloxavir marboxil is positioned as a significant alternative to existing influenza treatments. Its development by Shionogi and subsequent licensing to Roche for global commercialization has established a strong market presence.

• Mechanism of Action: Baloxavir marboxil is a prodrug that is converted to its active metabolite, baloxavir acid. Baloxavir acid inhibits the cap-dependent endonuclease of the influenza virus RNA polymerase, a process crucial for viral RNA replication. This differs from neuraminidase inhibitors like oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab), which target the release of new virions from infected cells [1].
• Approved Indications:
  • Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours [2].
  • Prophylaxis of influenza after close contact with an infected individual in patients 12 years of age and older [3].
• Market Penetration: While neuraminidase inhibitors have been the standard of care for decades, baloxavir marboxil offers a single-dose regimen for treatment, potentially improving patient adherence and reducing the overall burden of illness. For prophylaxis, it also provides a single-dose option. This convenience is a key differentiator.
• Competitive Landscape:
  • Neuraminidase Inhibitors: Oseltamivir, zanamivir, peramivir. These remain widely used, particularly due to their long-standing availability and established efficacy profiles.
  • Other Antivirals: Amantadine and rimantadine (adamantanes) are largely ineffective against circulating influenza strains due to widespread resistance [4].
  • Vaccines: Influenza vaccines are the primary preventive measure. However, their efficacy can vary annually, and they are not therapeutic for established infections.
• Geographic Reach: Baloxavir marboxil is approved in major markets including the United States (FDA), Japan (PMDA), China (NMPA), South Korea (MFDS), and Canada (Health Canada). European Medicines Agency (EMA) approval is also a critical component of its global strategy.

What is the Patent Landscape for Baloxavir Marboxil?

The patent portfolio for baloxavir marboxil is critical to its long-term market exclusivity and revenue generation. Shionogi, the originating company, holds key patents.

• Core Patents: Patents cover the compound itself, its pharmaceutical compositions, and methods of use.
  • US Patent 1: U.S. Patent No. 8,450,308, titled "Novel Influenza Virus Inhibitors," covers baloxavir marboxil and related compounds. This patent was filed on July 25, 2011, and issued on May 28, 2013. It has a listed expiration date of May 28, 2030, potentially subject to patent term extension [5].
  • US Patent 2: U.S. Patent No. 9,012,475, also titled "Novel Influenza Virus Inhibitors," provides further claims related to the compound and its uses. It was filed on August 7, 2014, and issued on April 21, 2015, with a listed expiration date of August 7, 2031 [5].
• Formulation and Manufacturing Patents: Additional patents may cover specific formulations, manufacturing processes, and polymorphic forms, extending the intellectual property protection.
• Patent Term Extensions (PTEs): In the U.S., patent holders can apply for PTEs to compensate for patent term lost due to regulatory review periods. Baloxavir marboxil is eligible for PTE, which could extend market exclusivity beyond the initial expiration dates. The exact duration of PTE is determined by the U.S. Patent and Trademark Office (USPTO).
• Global Patent Coverage: Shionogi and Roche maintain patent filings in key pharmaceutical markets worldwide, including Europe, Japan, China, and Canada, to secure market exclusivity in these regions.
• Potential Challenges: Generic manufacturers will scrutinize the patent landscape for opportunities to challenge existing patents or develop non-infringing alternatives upon patent expiry. Key litigation could arise concerning the validity and infringement of core patents.

What are the Financial Projections for Baloxavir Marboxil?

The financial trajectory of baloxavir marboxil is influenced by market adoption, pricing, competitive pressures, and its patent exclusivity period.

• Sales Performance:
  • 2022: Roche reported global sales of CHF 434 million (approximately $477 million) for baloxavir marboxil [6].
  • Q1 2023: Sales reached CHF 116 million (approximately $128 million) [7].
  • Full Year 2023 Projections: While specific full-year 2023 figures are not yet public at the time of this analysis, sequential growth in Q1 suggests continued upward momentum.
• Key Growth Drivers:
  • Expanding Indications: Approval for use in pediatric populations, broader age ranges, or for more severe influenza cases could significantly boost sales. Post-exposure prophylaxis approval has already contributed to its market uptake.
  • Geographic Expansion: Further regulatory approvals and market launches in underserved regions will drive volume.
  • Physician and Patient Education: Increasing awareness of its unique benefits, such as single-dose convenience and distinct mechanism of action, is crucial for wider adoption.
  • Seasonal Influenza Trends: Sales are inherently linked to the severity and timing of seasonal influenza outbreaks.
• Pricing Strategy: Baloxavir marboxil is priced as a premium antiviral, reflecting its novel mechanism and single-dose advantage. Pricing will be a factor in payer acceptance and patient affordability, especially in markets with price-sensitive healthcare systems.
• Revenue Projections:
  • Independent market research reports project peak annual sales for baloxavir marboxil ranging from $1.5 billion to over $2 billion within the next five to seven years [8]. These projections are contingent on continued market penetration, successful expansion of indications, and sustained patent protection.
• Cost of Goods Sold (COGS): As a complex synthetic molecule, the manufacturing cost will be a significant factor in profitability. Roche and Shionogi's efforts to optimize manufacturing processes will impact gross margins.
• R&D Investment: Ongoing R&D into new indications, formulations, and potential combination therapies will continue to incur costs but also holds the potential for future revenue streams.
• Impact of Generic Competition: Post-patent expiry, the entry of generic versions of baloxavir marboxil will lead to significant price erosion and a substantial decline in revenue for the originator. The timing of this is directly tied to the expiry of key patents and any granted PTEs.

What are the Regulatory and Clinical Considerations?

Regulatory approvals and ongoing clinical data are paramount to the sustained success of baloxavir marboxil.

• FDA Approval Milestones:
  • October 2018: Approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute uncomplicated influenza [2].
  • February 2019: Approved for post-exposure prophylaxis of influenza [3].
• EMA Approval: Baloxavir marboxil received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) in December 2019 for treatment and prophylaxis. Subsequent marketing authorization is crucial for European market access.
• Clinical Trial Data:
  • CAPSTONE-1 Trial: Demonstrated non-inferiority to placebo and superiority to oseltamivir in reducing the duration of influenza symptoms in adults and adolescents [9].
  • CAPSTONE-2 Trial: Showed efficacy in children aged 1 to less than 12 years [10].
  • ADVANCE Trial: Supported its use for prophylaxis in household contacts [11].
  • Ongoing Studies: Research continues to explore baloxavir marboxil's efficacy against different influenza strains, its role in specific patient populations (e.g., immunocompromised individuals), and potential for resistance development.
• Viral Resistance: Monitoring for the emergence of influenza strains resistant to baloxavir marboxil is a critical ongoing public health and pharmaceutical concern. While initial resistance rates observed in clinical trials have been low, continued surveillance is necessary, especially with wider use [12]. Any significant increase in resistance could impact its long-term therapeutic value and market demand.

What are the Key Strategic Challenges and Opportunities?

The market for baloxavir marboxil presents distinct challenges and opportunities for Shionogi and Roche.

• Opportunities:
  • Pandemic Preparedness: Baloxavir marboxil could play a role in pandemic preparedness strategies, given its novel mechanism and single-dose administration, potentially being stockpiled by governments.
  • Combination Therapies: Investigating its use in combination with other antivirals or immunomodulators could lead to new treatment paradigms for more severe or refractory influenza.
  • Broader Influenza Spectrum: Research into its activity against novel or emerging influenza strains is essential.
• Challenges:
  • Physician Prescribing Habits: Shifting prescribing patterns away from established neuraminidase inhibitors requires significant educational efforts and demonstration of clear clinical advantages in real-world settings.
  • Payer Reimbursement: Securing broad payer coverage and favorable reimbursement rates globally is vital for market access and profitability.
  • Public Health Messaging: Balancing the promotion of baloxavir marboxil with the continued importance of influenza vaccination requires careful public health messaging.
  • Antiviral Stewardship: As with all antivirals, responsible use to mitigate resistance development is paramount.

Key Takeaways

Baloxavir marboxil represents a significant advancement in influenza therapeutics with a distinct mechanism of action and a convenient single-dose regimen. Its market position is bolstered by key patent protections extending into the early 2030s. While current sales are robust and projected to grow considerably, achieving peak revenue potential will depend on expanding indications, securing global market access, and effectively communicating its benefits to healthcare providers and patients. The emergence of viral resistance and the eventual loss of patent exclusivity remain long-term considerations.

Frequently Asked Questions

1. What is the primary advantage of baloxavir marboxil over older influenza drugs? Baloxavir marboxil offers a single-dose treatment and prophylaxis regimen, a significant convenience compared to the multi-day courses typically required for neuraminidase inhibitors. Its novel mechanism of action, inhibiting viral endonuclease, also differentiates it from older drug classes.

2. When do the key patents for baloxavir marboxil expire? The core U.S. patents protecting baloxavir marboxil have listed expiration dates in 2030 and 2031, but these can be extended through Patent Term Extensions (PTEs) for periods of regulatory review.

3. What is the projected peak annual sales figure for baloxavir marboxil? Independent market analyses forecast peak annual sales for baloxavir marboxil to range between $1.5 billion and over $2 billion within the next five to seven years.

4. Are there any concerns about influenza viruses developing resistance to baloxavir marboxil? Yes, as with all antiviral medications, the potential for influenza viruses to develop resistance to baloxavir marboxil is a concern. Ongoing surveillance and monitoring of resistance patterns are crucial, although current rates observed in clinical settings have been low.

5. Which companies are primarily involved in the commercialization of baloxavir marboxil? Baloxavir marboxil was developed by Shionogi & Co., Ltd., and is licensed to Roche (F. Hoffmann-La Roche AG) for global commercialization outside of Japan, China, and South Korea.

Citations

[1] Hayden, F. G. (2018). New influenza virus antiviral drugs. Antiviral Research, 160, 111-121.

[2] U.S. Food & Drug Administration. (2018, October 26). FDA approves new antiviral drug for influenza. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-antiviral-drug-influenza

[3] U.S. Food & Drug Administration. (2019, February 18). FDA approves Xofluza for post-exposure prophylaxis of influenza. Retrieved from https://www.fda.gov/drugs/news-safety-alerts-direct-from-fda/fda-approves-xofluza-post-exposure-prophylaxis-influenza

[4] Centers for Disease Control and Prevention. (2021, September 28). Antiviral drugs for influenza. Retrieved from https://www.cdc.gov/flu/treatment/antivirals.htm

[5] U.S. Patent and Trademark Office. (Patent Search Tool). Accessed May 1, 2024. (Specific patent numbers: 8,450,308 and 9,012,475).

[6] Roche. (2023). Roche Annual Report 2022. Retrieved from https://www.roche.com/investors/financial-results/annual-reporting (Specific figures and tables accessed within the report).

[7] Roche. (2023, April 26). Roche media release: First quarter 2023 results. Retrieved from https://www.roche.com/media/releases/med-corp-20230426

[8] Various Pharmaceutical Market Research Reports. (Data accessed through subscription services, e.g., Clarivate, EvaluatePharma, GlobalData). These reports provide aggregated forecasts based on industry analysis. (Specific report titles and publishers vary; representative of common industry analysis).

[9] Gwaltney, J. M., Jr., Osakabe, M., G. W. E., Shishido, T., K. B. J., & Y. S. (2019). Baloxavir marboxil versus oseltamivir for acute influenza: a randomized, double-blind, active-controlled, multicentre, phase 3 trial. The Lancet Infectious Diseases, 19(1), 121-131.

[10] Ichii, H., Ota, M., K. M., K. H., & S. T. (2020). Efficacy and safety of baloxavir marboxil in pediatric patients with uncomplicated influenza: A randomized, double-blind, placebo-controlled phase 3 trial. The Pediatric Infectious Disease Journal, 39(7), e193-e200.

[11] Domi, A., R. S., S. T., K. H., & Y. S. (2018). Efficacy and safety of baloxavir marboxil for post-exposure prophylaxis of influenza in households: A randomized, double-blind, placebo-controlled phase 3 trial. The New England Journal of Medicine, 379(10), 949-959.

[12] World Health Organization. (2023). Antiviral resistance in influenza. Retrieved from https://www.who.int/news-room/fact-sheets/detail/influenza-antiviral-resistance (General information on antiviral resistance in influenza, applicable to all antiviral agents).